In a study in the journal Diabetes Technology & Therapeutics (DTT), investigators evaluated biomarkers for cardiovascular ...

Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.

Tirzepatide and semaglutide offer long-term health benefits but are not cost-effective, according to a study publi ...

Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and ...

Copycat versions of Eli Lilly’s diabetes drug Mounjaro and obesity drug Zepbound were supposed to go away this week. They’re ...

In a new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT), investigators evaluated biomarkers for ...

People without diabetes can lose up to 13% of their starting weight in 6 months using tirzepatide (Mounjaro) as an off-label ...

University of Chicago researchers assessed the long-term health outcomes and cost-effectiveness of four antiobesity ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they ...

Mounjaro and Trulicity are two injectable medications that treat type 2 diabetes. Learn more about their key similarities, ...

Lexaria Bioscience (LEXX) announced pharmacokinetic results from Human Study #3 or GLP-1-H24-3, comparing an oral version of ...